Weekly Top News – Psoriasis – March 2, 2020

topical roflumilast cream (ARQ-151) / ArcutisDERMIS-OLE: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (clinicaltrials.gov) - Feb 27, 2020 - P3; N=250; Enrolling by invitation; Sponsor: Arcutis Biotherapeutics, Inc.Cosentyx (secukinumab) / NovartisStudy to demonstrate the efficacy, safety and tolerability of intravenous secukinumab up to 52 weeks in subjects with active Psoriatic Arthritis (clinicaltrialsregister.eu) - Feb 29, 2020 - P3; N=380; Ongoing; Sponsor: Novartis Pharma AGTaltz (ixekizumab) / Eli LillyIXORA-R: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 27, 2020 - P4; N=1028; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting --> Completed